Improving the Paediatric Framework: Aligning Ambition with Reality in the Revision of the General Pharmaceutical Legislation
The EU’s chance to lead the way on rare diseases: Seizing the opportunity of the WHA Resolution
Expanding PRIME: Ensuring Faster Access to Orphan Medicinal Products in the EU
The importance of achieving a 180-day assessment timeline for medicines
From the EUCOPE Blog archives
Vitality of the EU Biotech Sector Depends on a Positive EU Policy Direction
September 9, 2024
Trans-Atlantic Perspectives on the Future of Pharma
August 24, 2023
The European Health Data Space (EHDS): Ensuring the digital transformation of healthcare in Europe
July 26, 2023
The Path to Innovation in Rare Diseases comes through Partnerships – A reflection on the EU Pharmaceutical Package
May 3, 2023
Rare Disease Day 2023: A Shared Vision for the EU Rare Disease Ecosystem
February 22, 2023
To the archives
